Hikal

Mumbai, India Founded: 1988 • Age: 38 yrs Listed
APIs and intermediates are produced via custom synthesis and research.

About Hikal

Hikal is a publicly listed company based in Mumbai (India) founded in 1988 by Jai Hiremath. APIs and intermediates are produced via custom synthesis and research. The company has 2,645 employees. Its website hikal.com draws about 10 thousand monthly visits. Its Indian entity Hikal Limited reported revenue of β‚Ή1,725 Cr. Hikal offers products and services including Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed competitors have raised funding.

Company details

Hikal was founded in 1988 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical and chemical sectors, where contract research, custom synthesis, and manufacturing of active pharmaceutical ingredients (APIs) and intermediates are conducted. Services extend to supplying ingredients for medicine production and providing research and development support for life sciences and biotechnology firms developing new products.

Recognitions & Rankings of Hikal

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#455
Valuation
₹6,788 Cr
  • Headquarters Mumbai, India
  • Employees 2,645
  • Founders Jai Hiremath
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website hikal.com
  • Social LinkedIn
  • Legal Name Hikal Limited
Key Metrics
  • Market Cap
    ₹2,738 Cr

    HIKAL · NSE

  • Share Price
    ₹220.76

    -0.59% today

  • Revenue
    ₹1,713 Cr

    FY 2025-26 · -7.9% YoY

  • EBITDA
    ₹135 Cr

    Margin 7.9%

  • Net Profit
    ₹27.20 Cr

    FY 2025-26 · -69.8% YoY

  • P/E (TTM)
    38.6x

    P/B 2.3x

  • ROE
    2.2%

    ROCE 3.4%

  • Debt / Equity
    0.59

    Interest cover -217.9x

  • Latest Funding Round
    $50M (USD), Post-IPO

    Nov 2021

  • Investors
  • Employee Count
    2,645

Products & Services of Hikal

Hikal offers a comprehensive portfolio of products and services, including Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products.

Contract Development & Manufacturing
Manufacturing Services

Offers custom manufacturing for pharmaceutical and chemical products

APIs and Intermediates
Chemical Products

Provides active pharmaceutical ingredients for various applications

Animal Health Products
Healthcare Services

Delivers intermediates and solutions for animal health sector

Funding Insights of Hikal

  • Total Rounds 3
  • Last Round Post-IPO β€” $50M
  • First Round $9.09M

    (Jun 2008)

  • Investors Count 1

All 3 funding rounds of Hikal with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Nov 2021$50MPost-IPO––
Jun 2013$10.34MPost-IPO––
Jun 2008$9.09MPost-IPO––
Valuation history

1 investors in total: 1 institutional.

Investors in Hikal

Hikal has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include International Finance Corporation.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
IFC is focused on private sector development in emerging markets.
1956ifc.org
Premium access

Investor details for Hikal

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Hikal Limited (Hikal)

Hikal Limited is the primary company behind Hikal. The boards of the 2 registered companies of Hikal currently have 12 directors; the longest-serving is Sameer Jai Hiremath, appointed in 1999. 14 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sameer Jai Hiremath
DIN 00062129
Managing Director26 May 199927 yrs 5 moHikal Limited
Sham Vinayak Wahalekar
DIN 00058031
Director18 Jun 200422 yrs 5 moHikal Pharmaceuticals Limited
Shivakumar Kheny
DIN 01487360
Director10 Jul 200422 yrs 4 moHikal Pharmaceuticals Limited
Ravindra Murgendra Khadabadi
DIN 00108205
Director22 Dec 200520 yrs 10 moHikal Pharmaceuticals Limited
Amit Babasaheb Kalyani
DIN 00089430
Director09 Feb 201214 yrs 9 moHikal Limited
Shivani Bhasin Sachdeva
DIN 00590500
Director01 Aug 20197 yrs 3 moHikal Limited
Shrikrishna Kiran Adivarekar
DIN 06928271
Director22 Dec 20214 yrs 10 moHikal Limited
Ramachandra Kaundinya Vinnakota
DIN 00043067
Director01 Oct 20233 yrs 1 moHikal Limited
Ravi Brijmohan Kapoor
DIN 01761752
Director11 Jan 20242 yrs 10 moHikal Limited
Ranjana Shivanand Salgaocar
DIN 00120120
Director23 Mar 20242 yrs 7 moHikal Limited
Suresh Sarangan
DIN 10562713
Whole-time director01 Apr 20242 yrs 7 moHikal Limited
Sandip Ashwinbhai Parikh
DIN 00030990
Director27 May 20265 moHikal Limited

People of Hikal

37 people are tracked at Hikal (15 in leadership, 11 in board & advisors, 11 in team); the tracked headcount is 2,645.

NameRoleGroup
FounderLeadership
Vidyanand Shetty
Head - Business Hr, Pharma Division, BangaloreLeadership
Vimal Kulshrestha
President, Crop ProtectionLeadership
Raghavendar Rao Morthala
Sr. Vice President And Head – CDMO R&t Pharma & Animal Health BULeadership
Nalin Diwan
General Manager (cdmo Business)Leadership
Abhijit Chandode
Operation HeadLeadership
Vinay Baliga
Senior Vice President FinanceLeadership
Manoj Mehrotra
President, PharmaceuticalsLeadership
Kuldeep Jain
CFOLeadership
Ratish Jha
President, Human ResourcesLeadership
Kailas Bharambe
Head Operations, Animal Health, PanoliLeadership
Anish Swadi
Senior President, Animal Health & Business TransformationLeadership
Anup Aurangabadkar
General Manager - HR & Admin, Research & Technology CentreLeadership
Kinjal Panchal
Deputy General Manager Human ResourcesLeadership
Sanchit Sinha
Senior General Manager & Head Corporate HRLeadership
Prakash Mehta
DirectorBoard & advisors
Sugandha Hiremath
DirectorBoard & advisors
Axel Kleemann
Scientific AdvisorBoard & advisors
Baba Kalyani
DirectorBoard & advisors
DirectorBoard & advisors

17 more people are available in the full profile.

Premium access

Complete people profiles for Hikal

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Hikal

Hikal is a publicly listed company on the NSE with ticker symbol HIKAL in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date14 Feb 2001
  • Listed onNSE: HIKAL
  • Listed entityHikal Limited
  • Exchange sectorHealth technology
  • ISININE475B01022
  • Share price₹218.68 (+2.61% on the day) · 2026-10-14
  • Market capitalisation₹2,629 Cr
  • Price to earnings276.0
  • EPS (diluted, trailing year)₹-2.74
  • Dividend yield0.28%
  • Volume (last session)267,708

Financials of Hikal

Exchange-reported figures of Hikal Limited, the listed company behind Hikal (NSE: HIKAL).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹1,713 Cr
-7.9% YoY
EBITDA
₹135 Cr
-58.8% YoY
Profit After Tax
₹27.20 Cr
-69.8% YoY
Net Worth
₹1,199 Cr
-5.0% YoY
Total Assets
₹1,990 Cr
-5.3% YoY
Total Debt
₹684 Cr
-10.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7131,8601,7852,0231,9431,7201,507
Revenue growth-7.9%+4.2%-11.8%+4.1%+12.9%+14.1%-
EBITDA135328267257341323258
EBITDA margin+7.9%+17.7%+15.0%+12.7%+17.5%+18.8%+17.1%
Profit before tax(78.30)12495.50105219206127
Net profit27.2090.1769.2377.9216013394.79
Net profit margin+1.6%+4.9%+3.9%+3.9%+8.3%+7.7%+6.3%
EPS (β‚Ή)(3.95)7.355.646.3613.0210.806.85
Balance sheet
Total assets1,9902,1022,0931,9501,7961,5661,481
Net worth1,1991,2621,1881,1331,068933816
Total debt684765818748675610646
Cash & bank13.8018.0020.8859.5549.0936.8163.57
Net working capital513601602536573569520
Cash flow
Cash from operations302280187315294229285
Cash from investing(145)(136)(174)(292)(284)(156)(164)
Cash from financing(160)(144)(27.00)(7.68)(5.56)(96.87)(101)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue434403519494318380552448
Revenue growth (YoY)+36.3%+5.9%-6.0%+10.4%-29.7%-6.5%--
Other income1.7010.706.602.801.901.000.503.60
EBITDA44.9037.0058.3044.707.2025.1012372.10
EBITDA margin+10.4%+9.3%+11.3%+9.1%+2.3%+6.8%+22.4%+16.4%
Depreciation41.7042.7042.0041.2041.2039.4037.7033.20
Interest13.4014.9014.6015.5014.9017.1017.9018.70
Profit before tax(8.50)(9.90)8.30(9.20)(47.00)(30.40)68.3023.80
Tax(2.40)(2.50)(6.10)(3.30)(12.10)(8.00)18.106.60
Net profit(6.10)(7.40)14.40(5.90)(34.90)(22.40)50.2017.20
EPS (β‚Ή)(0.49)(0.60)1.17(0.48)(2.83)(1.82)4.071.39
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7131,8601,7852,0231,9431,7201,507
Revenue growth-7.9%+4.2%-11.8%+4.1%+12.9%+14.1%-
EBITDA135328267257341323258
EBITDA margin+7.9%+17.7%+15.0%+12.7%+17.5%+18.8%+17.1%
Profit before tax(78.20)12495.40105219206127
Net profit27.3090.2769.0877.9216013394.80
Net profit margin+1.6%+4.9%+3.9%+3.9%+8.3%+7.7%+6.3%
EPS (β‚Ή)(3.94)7.365.636.3613.0210.806.85
Balance sheet
Total assets1,9902,1022,0921,9501,7961,5661,481
Net worth1,1991,2621,1881,1331,068933817
Total debt684765818748675610646
Cash & bank13.8017.9020.8059.5349.0936.8163.57
Net working capital513602602536573569520
Cash flow
Cash from operations302280187315294229285
Cash from investing(145)(136)(174)(292)(284)(156)(164)
Cash from financing(160)(144)(27.00)(7.68)(5.56)(96.87)(101)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue434403519494318380552448
Revenue growth (YoY)+36.3%+5.9%-6.0%+10.4%-29.7%-6.5%--
Other income1.7010.706.602.801.901.000.503.60
Total expenses389366461450311356429376
EBITDA44.8036.9058.5044.707.4024.8012472.20
EBITDA margin+10.4%+9.2%+11.3%+9.1%+2.3%+6.7%+22.5%+16.5%
Depreciation41.7042.7042.0041.2041.2039.4037.7033.20
Interest13.4014.9014.6015.5014.9017.1017.9018.70
Profit before tax(8.60)(10.00)8.50(9.20)(46.80)(30.70)68.4023.90
Tax(2.40)(2.50)(6.10)(3.30)(12.10)(8.00)18.106.60

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 20 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue434403519494318380552448
Revenue growth (YoY)+36.3%+5.9%-6.0%+10.4%-29.7%-6.5%--
Other income1.7010.706.602.801.901.000.503.60
EBITDA44.9037.0058.3044.707.2025.1012372.10
EBITDA margin+10.4%+9.3%+11.3%+9.1%+2.3%+6.8%+22.4%+16.4%
Depreciation41.7042.7042.0041.2041.2039.4037.7033.20
Interest13.4014.9014.6015.5014.9017.1017.9018.70
Profit before tax(8.50)(9.90)8.30(9.20)(47.00)(30.40)68.3023.80
Tax(2.40)(2.50)(6.10)(3.30)(12.10)(8.00)18.106.60
Net profit(6.10)(7.40)14.40(5.90)(34.90)(22.40)50.2017.20
EPS (β‚Ή)(0.49)(0.60)1.17(0.48)(2.83)(1.82)4.071.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7131,8601,7852,0231,9431,7201,507
Revenue growth-7.9%+4.2%-11.8%+4.1%+12.9%+14.1%-
Other income12.305.002.455.414.894.983.70
Total expenses1,5771,5311,5181,7661,6021,3981,250
Employee cost270247247222203164157
EBITDA135328267257341323258
EBITDA margin+7.9%+17.7%+15.0%+12.7%+17.5%+18.8%+17.1%
Depreciation16413411810995.6785.2582.46
Interest62.1075.2056.3748.1031.2236.2052.42
Profit before tax(78.30)12495.50105219206127
Tax(29.50)33.0025.9026.9958.0673.2842.14
Net profit27.2090.1769.2377.9216013394.79
Net profit margin+1.6%+4.9%+3.9%+3.9%+8.3%+7.7%+6.3%
EPS (β‚Ή)(3.95)7.355.646.3613.0210.806.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.7024.7024.6624.6624.6624.6624.66
Reserves & surplus1,1741,2381,1631,1091,043909792
Shareholders' funds (net worth)1,1991,2621,1881,1331,068933816
Minority interest0.000.000.000.000.000.000.00
Secured loans552630711663559514551
Unsecured loans13213410684.9911695.9494.92
Total debt684765818748675610646
Total liabilities1,9902,1022,0931,9501,7961,5661,481
Assets
Gross block2,4042,2251,8021,5641,3881,1281,065
Net block1,3331,3641,071948879713735
Capital work in progress94.50121414412295254161
Investments9.509.505.355.3010.910.610.68
Inventories358334304317329267312
Sundry debtors442522550442438486340
Cash & bank balances13.8018.0020.8859.5549.0936.8163.57
Loans & advances70.6012091.6712113889.5658.29
Total current assets884995967939954879775
Total current liabilities371394365403381310255
Net working capital513601602536573569520
Total assets1,9902,1022,0931,9501,7961,5661,481
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash13.0012.7026.7311.447.6431.6811.41
Net cash from operating activities302280187315294229285
Net cash from investing activities(145)(136)(174)(292)(284)(156)(164)
Net cash from financing activities(160)(144)(27.00)(7.68)(5.56)(96.87)(101)
Net change in cash(3.40)0.30(14.03)15.293.80(24.05)20.27
Closing cash13.8018.0020.8859.5549.0936.8163.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.9%+4.2%-11.8%+4.1%+12.9%+14.1%-
EBITDA growth-58.8%+23.0%+3.9%-24.5%+5.5%+25.3%-
PBT growth-+29.6%-9.4%-51.8%+5.9%+63.1%-15.1%
Net income growth-69.8%+30.3%-11.2%-51.4%+20.5%+40.4%-
Revenue CAGR (3Y)-5.4%-1.4%+1.2%+10.3%+6.9%+9.9%+14.1%
EBITDA CAGR (3Y)-19.3%-1.2%-6.1%-0.1%+4.5%+10.1%+9.9%
Profitability & leverage
Net income margin-2.9%+4.9%+3.9%+3.9%+8.3%+7.7%+5.6%
Return on capital employed+3.4%+9.5%+7.5%+8.2%+14.9%+15.9%+13.4%
Return on net worth+2.2%+7.4%+6.0%+7.1%+16.0%+15.2%+12.1%
Debt / equity0.590.650.670.650.640.720.83
Long-term debt / equity0.300.320.390.350.270.320.38
Interest cover-217.8938.7637.7332.4912.7515.2329.90
Efficiency & per share
Fixed asset turnover0.740.921.061.371.541.571.49
Inventory turnover4.955.835.756.276.525.944.45
Debtors turnover3.553.473.604.604.214.174.37
EPS (β‚Ή)(3.95)7.355.646.3613.0210.806.85
Dividend per share (β‚Ή)0.601.401.201.201.602.001.20
Book value per share (β‚Ή)97.07102.2196.3291.9386.6275.7066.22
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue434403519494318380552448
Revenue growth (YoY)+36.3%+5.9%-6.0%+10.4%-29.7%-6.5%--
Other income1.7010.706.602.801.901.000.503.60
Total expenses389366461450311356429376
EBITDA44.8036.9058.5044.707.4024.8012472.20
EBITDA margin+10.4%+9.2%+11.3%+9.1%+2.3%+6.7%+22.5%+16.5%
Depreciation41.7042.7042.0041.2041.2039.4037.7033.20
Interest13.4014.9014.6015.5014.9017.1017.9018.70
Profit before tax(8.60)(10.00)8.50(9.20)(46.80)(30.70)68.4023.90
Tax(2.40)(2.50)(6.10)(3.30)(12.10)(8.00)18.106.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7131,8601,7852,0231,9431,7201,507
Revenue growth-7.9%+4.2%-11.8%+4.1%+12.9%+14.1%-
Other income12.305.002.505.414.894.983.70
Total expenses1,5771,5311,5181,7661,6021,3981,250
Employee cost266242244220201164157
EBITDA135328267257341323258
EBITDA margin+7.9%+17.7%+15.0%+12.7%+17.5%+18.8%+17.1%
Depreciation16413411810995.6785.2582.46
Interest62.1075.2056.4048.1031.2236.2052.42
Profit before tax(78.20)12495.40105219206127
Tax(29.50)33.0025.9026.9958.0673.2842.14
Net profit27.3090.2769.0877.9216013394.80
Net profit margin+1.6%+4.9%+3.9%+3.9%+8.3%+7.7%+6.3%
EPS (β‚Ή)(3.94)7.365.636.3613.0210.806.85
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital24.7024.7024.7024.6624.6624.6624.66
Reserves & surplus1,1741,2381,1631,1091,043909792
Shareholders' funds (net worth)1,1991,2621,1881,1331,068933817
Secured loans552630712663559514551
Unsecured loans13213410684.9911695.9494.92
Total debt684765818748675610646
Total liabilities1,9902,1022,0921,9501,7961,5661,481
Assets
Gross block2,4042,2251,8021,5641,3881,1281,065
Net block1,3331,3641,071948879713735
Capital work in progress94.50121414412295254161
Investments9.509.505.405.3110.920.620.69
Inventories358334304317329267312
Sundry debtors442522550442438486340
Cash & bank balances13.8017.9020.8059.5349.0936.8163.57
Loans & advances70.6012291.7012113889.5658.29
Total current assets884997966939954879775
Total current liabilities371395364403381310255
Net working capital513602602536573569520
Total assets1,9902,1022,0921,9501,7961,5661,481
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.9012.6026.7011.447.6431.6811.41
Net cash from operating activities302280187315294229285
Net cash from investing activities(145)(136)(174)(292)(284)(156)(164)
Net cash from financing activities(160)(144)(27.00)(7.68)(5.56)(96.87)(101)
Net change in cash(3.30)0.30(14.10)15.273.80(24.05)20.27
Closing cash13.8017.9020.8059.5349.0936.8163.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.9%+4.2%-11.8%+4.1%+12.9%+14.1%-
EBITDA growth-58.8%+23.1%+3.8%-24.5%+5.5%+25.3%-
PBT growth-+29.9%-9.5%-51.8%+5.9%+63.1%-15.1%
Net income growth-69.8%+30.7%-11.3%-51.4%+20.5%+40.4%-
Revenue CAGR (3Y)-5.4%-1.4%+1.2%+10.3%+6.9%+9.9%+14.1%
EBITDA CAGR (3Y)-19.2%-1.2%-6.2%-0.1%+4.5%+10.1%+9.3%
Profitability & leverage
Net income margin-2.8%+4.9%+3.9%+3.9%+8.3%+7.7%+5.6%
Return on capital employed+3.4%+9.5%+7.5%+8.2%+14.9%+15.9%+13.4%
Return on net worth+2.2%+7.4%+6.0%+7.1%+16.0%+15.2%+12.1%
Debt / equity0.590.650.670.650.640.720.83
Long-term debt / equity0.300.320.390.350.270.320.38
Interest cover-218.6638.7437.7832.4912.7515.2329.90
Efficiency & per share
Fixed asset turnover0.740.921.061.371.541.571.49
Inventory turnover4.955.835.756.276.525.944.45
Debtors turnover3.553.473.604.604.214.174.37
EPS (β‚Ή)(3.94)7.365.636.3613.0210.806.85
Dividend per share (β‚Ή)0.601.401.201.201.602.001.20
Book value per share (β‚Ή)97.09102.2096.1691.9386.6275.7066.22

Timeline of Hikal

4 dated milestones of Hikal across 33 years, from founding to its latest funding, stage changes and deals.

  1. Founded Hikal is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $9.1M.
  4. Funding Latest funding round, Post-IPO, of $50.0M.

Competitors of Hikal

Hikal has 3 listed competitors in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed competitors of Hikal

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Hikal

The website of Hikal (hikal.com) receives about 10.3K visits a month.

  • Monthly visits
    10.3K

    ▼ 5.8% vs previous month

Similar websites

Websites whose visitors overlap most with Hikal. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
valsynthese.ch
valsynthese.ch
100%
–
kalyanisteels.com
73%
8.1K#1,716,744View details
bharatforge.com
73%
27.5K#733,394View details
panchsheelorganics.com
29%
21.5K#1,592,649View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Hikal (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Hikal

HIKAL: Q2 CONS NET LOSS 61M RUPEES VS LOSS 349M (YOY)
Exchange Update β€’ 18 days ago
HIKAL: Q2 EBITDA 450M RUPEES VS 72M (YOY); Q2 EBITDA MARGIN 10.34% VS 2.3% (YOY)
Exchange Update β€’ 18 days ago
Hikal: Co Reiterates FY27 Guidance Of Mid-teen Revenue Growth, With H2 Growth Expected To Exceed Last Year
Exchange Update β€’ 18 days ago
Hikal: Co Reiterates Fy27 Guidance Of Mid-teen Revenue Growth, With H2 Growth Expected To Exceed Last Year
Exchange Update β€’ 18 days ago
Hikal: Bengaluru API Facility Receives Swissmedic GMP Certification, Unlocks Potential in European Regulated Markets.
Exchange Update β€’ 22 days ago
HIKAL: Company Shareholders Approve Sameer Hiremath As Chairman & Managing Director For Five Years Starting October 1.
Exchange Update β€’ 1 month ago
HIKAL: Starts Production At New CGMP Plant In Panoli For Personal Care Items, Entering The Global Beauty Sector; Initial Focus Is On Skin Care With Advanced UV Filters And Customers Are Happy.
Exchange Update β€’ 2 months ago
Premium access

Complete news archive for Hikal

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hikal

Hikal was founded in 1988 and raised its 1st funding round 20 years after it was founded.

Hikal is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Hikal has 2,645 employees.

The primary company behind Hikal, Hikal Limited, reported revenue of β‚Ή1,725 Cr for FY 2026, down 8% year on year.

Hikal was founded in 1988 and is headquartered in Mumbai, India. Operations focus on the pharmaceutical and chemical sectors, where contract research, custom synthesis, and manufacturing of active pharmaceutical ingredients (APIs) and intermediates are conducted. Services extend to supplying ingredients for medicine production and providing research and development support for life sciences and biotechnology firms developing new products.

Hikal's top competitors include Laurus Labs, Symbiotec and SeQuent.

Hikal offers Contract Development & Manufacturing, APIs and Intermediates, and Animal Health Products.

Yes, Hikal is publicly traded on NSE under the ticker symbol HIKAL.

Hikal has 1 investor. Key investors include International Finance Corporation.

Hikal is associated with 2 legal entities: Hikal Limited, Hikal Pharmaceuticals Limited.

The legal entities of Hikal currently have 14 directors, including Shivani Bhasin Sachdeva, Sameer Jai Hiremath, Amit Babasaheb Kalyani and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available